{
    "braf_related_treatments": [
      {
        "name": "Encorafenib (Braftovi)",
        "type": "BRAF inhibitor",
        "mechanism": "Selectively inhibits BRAF V600E kinase activity",
        "efficacy": "Median OS of 9.3 months as monotherapy",
        "approvalStatus": "FDA Approved",
        "url": "https://www.braftovi.com/"
      },
      {
        "name": "Cetuximab (Erbitux)",
        "type": "EGFR inhibitor (monoclonal antibody)",
        "mechanism": "Binds to EGFR and blocks ligand binding",
        "efficacy": "Objective response rate of 26.8% when combined with encorafenib",
        "approvalStatus": "FDA Approved",
        "url": "https://www.erbitux.com/"
      },
      {
        "name": "Binimetinib (Mektovi)",
        "type": "MEK inhibitor",
        "mechanism": "Inhibits MEK1 and MEK2 activation and kinase activity",
        "efficacy": "Marginal additional benefit when added to encorafenib and cetuximab",
        "approvalStatus": "FDA Approved",
        "url": "https://www.mektovi.com/"
      }
    ]
  }
  